Published in Lung Cancer on August 01, 2003
Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer (2005) 1.02
Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer (2006) 0.98
Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol (2004) 0.82
Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA (2010) 10.97
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol (2005) 2.98
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys (2010) 2.84
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol (2011) 2.21
Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer. Acta Oncol (2006) 1.77
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol (2013) 1.75
Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.69
A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys (2010) 1.64
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol (2010) 1.63
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst (2010) 1.59
Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol (2013) 1.50
Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest (2004) 1.48
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res (2009) 1.27
A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys (2010) 1.26
Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys (2013) 1.24
Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol (2015) 1.19
Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol (2012) 1.11
Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys (2012) 1.06
Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol (2006) 1.03
Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys (2012) 1.02
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer (2005) 1.00
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Int J Radiat Oncol Biol Phys (2012) 0.98
Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clin Lung Cancer (2008) 0.97
SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia (2007) 0.93
Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol (2004) 0.90
Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol (2002) 0.90
Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization. Semin Radiat Oncol (2010) 0.90
Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer (2005) 0.89
Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. J Urol (2006) 0.89
Stereotactic body radiation therapy for thoracic cancers: recommendations for patient selection, setup and therapy. Front Radiat Ther Oncol (2011) 0.88
The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells. Cancer Res (2006) 0.88
Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib. Indian J Biochem Biophys (2005) 0.87
The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials. J Thorac Oncol (2010) 0.85
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer. Am J Clin Oncol (2003) 0.84
Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res (2002) 0.84
Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells. Radiother Oncol (2003) 0.83
Cetuximab in combination therapy: from bench to clinic. Cancer Metastasis Rev (2010) 0.82
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer. Cancer Res Treat (2012) 0.82
Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2005) 0.82
Erratum. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys (2016) 0.82
Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer. Oncology (Williston Park) (2002) 0.81
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol (2009) 0.80
Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. Clin Lung Cancer (2011) 0.80
Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. J Neurooncol (2014) 0.80
Stereotactic ablative body radiation therapy for tumors in the lung in octogenarians: a retrospective single institution study. BMC Cancer (2014) 0.79
A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92. J Thorac Oncol (2013) 0.79
Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys (2004) 0.79
Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer (2002) 0.79
Non-small cell lung cancer and central nervous system metastases: should we be using prophylactic cranial irradiation? Semin Radiat Oncol (2004) 0.78
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer. Oncology (Williston Park) (2004) 0.78
Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study. J Appl Clin Med Phys (2004) 0.78
The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide adenine dinucleotide phosphate oxidase activity. Cancer Res (2003) 0.78
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer (2008) 0.77
Prophylactic cranial irradiation with combined modality therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol (2005) 0.77
Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer (2008) 0.77
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother Oncol (2002) 0.77
4-Dimensional conformal radiation therapy: image-guided radiation therapy and its application in lung cancer treatment. Clin Lung Cancer (2006) 0.77
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol (2008) 0.77
Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer (2002) 0.77
Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer (2009) 0.77
DNA-PKcs-dependent modulation of cellular radiosensitivity by a selective cyclooxygenase-2 inhibitor. Int J Radiat Oncol Biol Phys (2007) 0.76
Sustained metaphase arrest in response to ionizing radiation in a non-small cell lung cancer cell line. Radiat Res (2008) 0.76
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 0.76
Potential for combined modality therapy of cyclooxygenase inhibitors and radiation. Prog Exp Tumor Res (2003) 0.76
Effect of PF-02341066 and radiation on non-small cell lung cancer cells. Oncol Rep (2012) 0.76
Combined modality therapy for non-small cell lung cancer, past, present, and future. Lung Cancer (2003) 0.76
Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. Cancer Biol Ther (2015) 0.75
In reply to Zagar and Marks. Int J Radiat Oncol Biol Phys (2012) 0.75
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin Lung Cancer (2009) 0.75
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. Int J Radiat Oncol Biol Phys (2005) 0.75
Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer. Curr Oncol Rep (2003) 0.75
Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Cancer Res Treat (2003) 0.75
A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiother Oncol (2005) 0.75
Multi-objective radiomics model for predicting distant failure in lung SBRT. Phys Med Biol (2017) 0.75
Summary of presentations from the 11th targeted therapies for lung cancer meeting: radiation oncology. J Thorac Oncol (2011) 0.75